Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)

Lung Cancer Clinical Trial

Official title:

γδ T Cell Immunotherapy for Treatment of

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02425748
• Other study ID #: Gd T cell and lung cancer
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: June 8, 2017
• Est. completion date: June 20, 2019

Study information

• Verified date: June 2018
• Source: Fuda Cancer Hospital, Guangzhou
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, effects of γδT cells on human non small lung cancer ( without EGFR mutation) in combination with tumor reducing surgery, for example cryosurgery going to be investigated.

Description:

Non small lung cancer will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as immunotherapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 20, 2019
• Est. primary completion date: December 20, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age:18-75

2. Karnofsky performance status >50

3. Diagnosis with non small lung tumors based on histology or the current accepted radiological measures.

4. Classification tumor,nodes,metastasis-classification(TNM) stage: ?,?,? Will receive cryosurgery, gd Tcells/ DC-CIK.

5. Life expectancy: Greater than 3 months

6. Ability to understand the study protocol and a willingness to sign a written informed consent document

Exclusion Criteria:

1. Patients with other kinds of cancer

2. History of coagulation disorders or anemia

3. Patients with heart disease and diabetes

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Biological:
• DC-CIK
DC-CIK cells will be used against tumor cells.
• ?d T Cell
?d T cells will be used against non small lung tumor.
• ?d T/DC-CIK cells
?d T/DC-CIK cells will be used against lung tumor.

Locations

Country	Name	City	State
China	Biological treatment center in Fuda cancer hospital	Guangzhou	Guangdong

Sponsors (2)

Lead Sponsor	Collaborator
Fuda Cancer Hospital, Guangzhou	Jinan University Guangzhou

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduced size of the tumor.		Up to one year